Hitta i sidan


    Bergqvist J, Iderberg H, Mesterton J, Bengtsson N, Wettermark B, Henriksson R. Healthcare resource use, comorbidity, treatment and clinical outcomes for patients with primary intracranial tumors: a Swedish population-based register study. Acta Oncol. 2016 Dec 7:1-10 [Epub ahead of print] PubMed

    Komen J, Forslund T, Hjemdahl P, Andersen M, Wettermark B. Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. Br J Clin Pharmacol. 2016 Oct 11. doi: 10.1111/bcp.13150. [Epub ahead of print] PubMed

    Vancheri F, Backlund L, Strender LE, Godman B, Wettermark B. Time trends in statin utilisation and coronary mortality in Western European countries.. BMJ Open 2016;6:e010500. PubMed

    Citarella A, Linder M, Kieler H, Berglind IA, Sundström A, Wettermark B, Andersen M.. Influence of baseline Low Density Lipoprotein cholesterol values on statin therapy persistence. Eur J Clin Pharmacol 2016;72:349-57. PubMed

    Forslund T, Wettermark B, Hjemdahl P. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016;72:329-38. PubMed

    Jablonska B, Kosidou K, Ponce de Leon A, Wettermark B, Magnusson C, Dal H, et al. Neighbourhood socioeconomic characteristics and utilization of ADHD medication in schoolchildren - a population multilevel study in Stockholm County. J Atten Disord. 2016 Apr 19. pii: 1087054716643257. [Epub ahead of print] PubMed

    Lantz M, Calissendorff J, Träisk F, Tallstedt L, Planck T, Törring O, et al. Adjuvant Treatment of Graves' Disease with Diclofenac: Safety, Effects on ophtalmopathy and Antibody Concentrations . Eur Thyroid J 2016;5:50-56. PubMed

    Wallander, M, Axelsson K, Nilsson A, Lundh D, Lorentzon M. Type 2 diabetes and risk of hip fractures and non-skeletal fall injuries in the elderly - a study from the Fractures and fall injuries in the elderly cohort (FRAILCO). J Bone Miner Res. 2017 Mar;32(3):449-460. PubMed

    Wändell P, Carlsson AC, Holzmann MJ, Ärnlöv J, Johansson SE, Sundquist J, et al. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation - a cohort study in primary care. Eur J Clin Pharmacol. 2017 Feb;73(2):215-221. PubMed

    Wändell P, Carlsson AC, Holzmann MJ, Ärnlöv J, Johansson SE, Sundquist J, et al. Warfarin treatment and risk of stroke among primary care patients with atrial fibrillation. Scand Cardiovasc J. 2016 Oct - Dec;50(5-6):311-316. PubMed

    Wändell P, Carlsson AC, Holzmann MJ, Ärnlöv J, Johansson SE, Sundquist J, et al. Warfarin treatment and risk of myocardial infarction - a cohort study of patients with atrial fibrillation treated in primary health care. Int J Cardiol. 2016 Oct 15;221:789-93. PubMed

    Gasparini A, Evans M, Coresh J, Grams ME, Norin O, Qureshi AR, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transplant. 2016 Dec;31(12):2086-2094. PubMed

    Evans M, Carrero JJ, Bellocco R, Barany P, Qureshi AR, Seeberger A, et al. Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients. Nephrol Dial Transplant. 2016 Sep 26. PubMed

    Pohanka A, Rosenborg S, Lindh JD, Beck O. Experiences from using LC-MS/MS for analysis of immunosuppressive drugs in a TDM service. Clin Biochem. 2016 Sep;49(13-14):1024-31. PubMed

    Rashid MU, Rosenborg S, Panagiotidis G, Holm J, Söderberg Löfdal K, et al. Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4244-51. PubMed

    Evans M, Carrero JJ, Szummer K, Åkerblom A, Edfors R, Spaak J, et al. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. J Am Coll Cardiol. 2016 Apr 12;67(14):1687-97. PubMed

    Evans M, Suttorp MM, Bellocco R, Hoekstra T, Qureshi AR, Dekker FW, et al. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013. Nephrol Dial Transplant. 2016 Apr;31(4):628-35. PubMed

    Runesson B, Gasparini A, Qureshi AR, Norin O, Evans M, Barany P, et al. The Stockholm CREAtinine Measurements (SCREAM) project: protocol overview and regional representativeness. Clin Kidney J. 2016 Feb;9(1):119-27. PubMed

    Rydberg DM, Holm L, Engqvist I, Fryckstedt J, Lindh JD, Stiller CO, et al. Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting. PLoS One. 2016;11:e0162948. PubMed

    Cars T, Wettermark B, Löfberg R, Eriksson I, Sundström J, Lördal M. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2016 May;10(5):556-65. PubMed

    Holmqvist L, Bengtsson Boström K, Kahan T, Schiöler L, Hasselström J, Hjerpe P, et al. Prevalence of treatment resistant hypertension, and important associated factors - Results from the Swedish Primary Care cardiovascular Database (SPCCD). J J Am Soc Hypertens. 2016 Nov;10(11):838-846. PubMed

    Qvarnström M, Kahan T, Kieler H, Brandt, L, Hasselström J, Bengtsson Boström K, et al. Persistence to antihypertensive drug classes: A cohort study using the Swedish Primary Care Cardiovascular Database (SPCCD). Medicine (Baltimore). 2016 Oct;95(40). PubMed

    Bokrantz T, Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, et al. Thiazide diuretics and fracture-risk among hypertensive patients. Results from the Swedish primary care cardiovascular database (SPCCD). J Hypertens. 2017 Jan;35(1):188-197. PubMed

    Zarrinkoub R, Kahan T, Johansson S-E, Wändell P, Mejhert M, Wettermark B. How to best assess quality of drug treatment in patients with heart failure. Eur J Clin Pharmacol. 2016 Aug;72(8):965-75. PubMed

    Al-Aieshy F, Malmström RE, Antovic J, Pohanka A, Rönquist-Nii Y, Berndtsson M, et al. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol. 2016 Jun;72(6):671-9. PubMed

    Matusewicz W, Godman B, Pedersen HB, Fürst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8. PubMed

    Godman B, Malmström RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94. PubMed

    Šinigoj P, Malmström RE, Vene N, Rönquist-Nii Y, Božič-Mijovski M, Pohanka A, et al. Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillation. Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):323-9. PubMed

    Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Rönquist-Nii Y, Söderblom L, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015 Jul;136(1):148-53. PubMed

    Frisk P, Sporrong SK, Ljunggren G, Wettermark B, von Euler M. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden. Eur J Clin Pharmacol. 2016 Jun;72(6):747-54. PubMed

    Dahlén E, Wettermark B, Bergström A, Jonsson EW, Almqvist C, Kull I. Medicine use and disease control among adolescents with asthma. Eur J Clin Pharmacol. 2016 Mar;72(3):339-47. PubMed


    Saracco A, Szabó BK, Aspelin P, Leifland K, Tánczos E, Wilczek B, Axelsson R. Contrast-enhanced ultrasound using real-time contrast harmonic imaging in invasive breast cancer: comparison of enhancement dynamics with three different doses of contrast agent. Acta Radiol. 2015;56:34-41. PubMed

    Svensson A, Cederlund K, Aspelin P, Nyman U, Brismar TB. The effect of arm positioning on timing and enhancement of intravenous contrast media at coronary computed tomography angiography. Acta Radiol. 2015. PubMed

    Thor D, Brismar TB, Fischer MA. Low Tube Voltage Dual Source Computed Tomography to Reduce Contrast Media Doses in Adult Abdomen Examinations: A phantom study. Medical Physcis. 2015;42:5100. PubMed

    Nyman U, Aspelin P, Jakobsen J, Björk J. Controversies in contrast material-induced acute kidney injury: propensity score matching of patients with different dose/absolute glomerular filtration rate ratios. Radiology. 2015;277:633-7. PubMed

    Kahan T. Safety of digoxin use in patients with hypertensive heart disease and atrial fibrillation. J Hypertens. 2015;33:1371-72. PubMed

    Mejhert M, Kahan T. A management programme for suspected heart failure in primary care in cooperation with specialists in cardiology. Eur J Gen Pract.  2015;21:26-32. PubMed

    Andersson ML, Böttiger Y, Bastholm-Rahmner P, Ovesjö ML, Vég A, Eiermann B. Evaluation of usage patterns and user perception of the drug-drug interaction database SFINX. Int J Med Inform. 2015 ;84:327-33. PubMed

    Shemeikka T, Bastholm-Rahmner P, Elinder CG, Vég A, Törnqvist E, Cornelius B et al. A health record integrated clinical decision support system to support prescriptions of pharmaceutical drugs in patients with reduced renal function: design, development and proof of concept. Int J Med Inform. 2015;84:387-95. PubMed

    Nörby U, Källén K, Shemeikka T, Korkmaz S, Winbladh B. Pregnant women's view on the Swedish internet resource Drugs and Birth Defects intended for health care professionals. Acta Obstet Gynecol Scand. 2015;94:960-8. PubMed

    Lilja B, Miranda-Téllez J, Ljunggren G, Lööv S, Wettermark B, Lissmats A, Henriksson R. A pharmacoepidemiological study on cancer patients by linking multiple data sources in the capital region of Sweden. Adv Pharmacoepidemiol Drug Saf. 2015, 4:4. 

    Bergendal A, Schiöler H, Wettermark B, Björkstén K. Concomitant use of two or more antipsychotic drugs in the Swedish population. Ther Adv Psychopharmacol. 2015;5:224-31. PubMed

    Roll M, Rosenqvist M, Sjöborg B, Wettermark B. Young adults with acute unexplained chest pain - disease patterns and drug utilization 25 years later. Psychosom Med. 2015;77:567-74. PubMed

    Campbell SM, Godman B, Diogene E, Fürst J, Gustafsson LL, MacBride-Stewart S et al. Quality indicators as a tool in improving the introduction of new medicines. Basic Clin Pharmacol Toxicol. 2015;116:146-57. PubMed

    Kardakis T, Tomson G, Wettermark B, Brommels M, Godman B, Bastholm-Rahmner P. The establishment and expansion of an innovative centre for rational pharmacotherapy –  determinants and challenges. Int J Health Plann Manage. 2015;30:14-30. PubMed


    Rosenborg S, Nordström A, Almquist T, Wennberg L, Bárány P. Systematic conversion to generic tacrolimus in stable kidney transplant recipients. Clin Kidney J. 2014 Apr;7(2):151-155. PubMed

    Fehrman-Ekholm I, Wadström JAlkas J, Elinder CG. Eculizumab prevented recurrence of atypical hemolytic uremic syndrome in a kidney donor after a third kidney transplantation. Austin J Nephrol Hypertens. 2014. 1(4). Journal

    Elinder CG, Barany P, Heimburger O. The use of estimated glomerular filtration rate for dose adjustment of medications in the elderly. Drugs Aging. 2014. 31(7): p. 493-9. PubMed

    Lenander C, Elfsson B, Danielsson B, Midlöv P, Hasselström J. Effects of a pharmacist-led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care. 2014;32(4):180-6. PubMed

    Godman B, Malmström RE, Diogene E, Jayathissa S, McTaggart S, Cars T et al. Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Front Pharmacol. 2014 Jun 10;5:109. PubMed

    Godman B, Petzold M, Bennett K, Bennie M, Bucsics A, Finlayson AE et al. Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med. 2014 Jun 13;12:98. PubMed

    Moon JC, Godman B, Petzold M, Alvarez-Madrazo S, Bennett K, Bishop I et al. Different initiatives across Europe to enhance losartan utilization post generics: impact and implications. Front Pharmacol. 2014 Oct 8;5:219. PubMed

    Lövström R, Hoffmann M, Gustafsson LL. Kliniska beslutsstöd kan ge hjälp i den komplexa vården [Clinical decision support can provide assistance in complex health care]. Läkartidningen. 2014 Oct 22-28;111(43):1906-10. PubMed

    Andersén P, Bäckström T, Dahlquist G, Damber JE, Engström-Laurent A, Gustafson Y et al. Svensk medicinsk forskning behöver inte mer styrning [Swedish medical research does not need more control]. Läkartidningen. 2014 May 27-Jun 10;111(22-23):980-1. PubMed

    Dalén M, Hjemdahl P, Holmström M, Ivert T. Blödning och kirurgi vid behandling med nya perorala antikoagulantia Handläggningen kan kompliceras av att specifika antidoter saknas  [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes]. Läkartidningen. 2014 Jun 11-17;111(24):1064-8. PubMed

    Skeppholm M, Hjemdahl P, Antovic JP, Muhrbeck J, Eintrei J, Rönquist-Nii Y et al. On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation. Thromb Res. 2014;134:783-9. PubMed

    Helldén A, Al-Aieshy F, Bastholm-Rahmner P, Bergman U, Gustafsson LL, Sjöviker S et al. Elektroniskt stöd i journalen för dosering av läkemedel vid sänkt njurfunktion. [Electronic support in the medical record for drug dosage in renal failure]. Läkartidningen. 2014;111. PubMed

    Wettermark B, Brandt L, Kieler H, Bodén R. Pregabalin is increasingly prescribed for neuropathic pain, generalized anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014;68:104-10. PubMed

    Frisk P, Kälvemark-Sporrong S, Wettermark B. Selection bias in pharmacy-based patient surveys. Pharmacoepidemiol Drug Saf. 2014; 23: 128-139. PubMed

    Godman B, Wettermark B, Van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106. PubMed

    von Euler M, Keshani S, Baatz K, Wettermark B. Utilization of Triptanes in Sweden; analyses of over the counter and prescriptions sales. Pharmacoepidemiol Drug Saf. 2014;23:1288-93. PubMed

    Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with warfarin and aspirin in patients with atrial fibrillation at different CHA2DS2VASc-scores: experience from the Stockholm region. Eur J Clin Pharmacol. 2014;70:1477-85. PubMed

    Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B et al. Gender differences in antihypertensive drug treatment: Results from the Swedish primary care cardiovascular database (SPCCD). Am Soc Hypertens. 2014;8:882-90s. PubMed

    Forslund F. Von Euler M, Johnsson H, Holmström M, Wettermark B, Hjemdahl P. Fler med förmaksflimmer får antikoagulantia sedan NOAK kom. Läkartidningen. 2015;112:CZYS

    Ljungman C, Kahan T, Schiöler L, Hjerpe P, Hasselström J, Wettermark B, et al. Gender differences in antihypertensive drug treatment: Results from the Swedish primary care cardiovascular database (SPCCD). J Am Soc Hypertens. 2014 Dec;8(12):882-90. PubMed

    Ljungman C, Kahan T, Schiöler L, Hjerpe P, Wettermark B, Boström KB, et al. Antihypertensive treatment and control according to gender, education, country of birth and psychiatric disorder: the Swedish Primary Care Cardiovascular Database (SPCCD). J Hum Hypertens. 2015 Jun;29(6):385-93. PubMed

    Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risks for stroke and bleeding with Warfarin and Aspirin in Patients with Atrial Fibrillation at Different CHA2DS2VASc-scores: Experience from the Stockholm Region. Eur J Clin Pharmacol. 2014 Dec;70(12):1477-85. PubMed

    von Euler M, Keshani S, Baatz K, Wettermark B. Utilization of Triptanes in Sweden; analyses of over the counter and prescriptions sales. Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1288-93. PubMed

    Godman B, Wettermark B, Van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014 Jun 17;5:106. PubMed

    Hasselström J, Zarrinkoub R, Holmquist C, Hjerpe P, Ljungman C, Qvarnström M, et al. The Swedish Primary Care Cardiovascular Database (SPCCD); 74 751 hypertensive primary care patients. Blood Press 2014 Apr;23(2):116-25. PubMed

    Hjemdahl P, Andersén-Karlsson E. Paradigmskifte med de nya amerikanska riktlinjerna för lipidsänkande behandling [Paradigm shift with the new American guidelines for lipid-lowering therapy]. Läkartidningen 2014 Apr 2-8;111(14):596-7

    Holmström IK, Bastholm-Rahmner P, Bernsten C, Röing M, Björkman I. Swedish teenagers and over-the-counter analgesics - responsible, casual or careless use. Res Social Adm Pharm 2014 Mar-Apr;10(2):408-18. PubMed

    Dahlen E, Almqvist C, Bergström A, Wettermark B, Kull I. Factors associated with high concordance between parental-reported use and dispensed asthma drugs in adolescents: Findings from the BAMSE birth cohort. Pharmacoepidemiol Drug Saf. 2014 Jun 6. doi: 10.1002/pds.3662. [Epub ahead of print] PubMed

    Freund-Levi Y, Jedenius E, Tysen-Bäckström AC, Lärksäter M, Wahlund LO, Eriksdotter M. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry. 2014; 22 (4): 341-8. PubMed

    Freund-Levi Y, Bloniecki V, Auestad B, Tysen Bäckström AC, Lärksäter M, Aarsland D. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement Geriatr Cogn Disord. 2014; 38(3-4): 234-44. PubMed

    Frisk P, Kälvemark-Sporrong S, Wettermark B. Selection bias in pharmacy-based patient surveys. Pharmacoepidemiol Drug Saf. 2014 Feb;23(2):128-39. PubMed

    Karlsson L, Wettermark B, Tomson T. Drug treatment in patients with newly diagnosed unprovoked seizures/epilepsy. Epilepsy Res 2014 Mar 27. pii: S0920-1211(14)00078-3. [Epub ahead of print] PubMed

    Vancheri F, Wettermark B, Strender LE, Backlund LG. Trends in coronary heart disease mortality and statin utilization in two European areas with different population risk levels: Stockholm and Sicily. International Cardiovascular Forum 2014.

    Rydberg DM, Holm L, Mejyr S, Loikas D, Schenck-Gustafsson K, von Euler M, et al. Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. Eur J Clin Pharmacol 2014 Jan;70(1):117-26. PubMed

    Wettermark B, Brandt L, Kieler H, Bodén R. Pregabalin is increasingly prescribed for neuropathic pain, generalized anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract. 2014 Jan;68(1):104-10. PubMed


    Nörby U, Källén K, Eiermann B, Korkmaz S, Winbladh B, Gustafsson LL. Drugs and Birth Defects: a knowledge database providing risk assessments based on national health registers. Eur J Clin Pharmacol. 2013 Apr;69(4):889-99. PubMed

    Elinder C-G, Barany P, and Heimburger O. Bättre använda modern formel än att vara formell. [It is better use a modern formula than being formal]. Lakartidningen, 2013. 110(47): p. 2122.

    Elinder C-G, Barany P, and Heimburger O. Dosering av läkemedel bör anpassas till njurfunktionen [Drug dosage should be based on renal function] Lakartidningen, 2013. 110(47): p. 2119-20

    Barany P, Elinder C-G, Samuelsson O. Behandling med cinacalcet vid sekundär hyperparatyroidism hos dialyspatienter: Viljan god – men evidensen då? [Treatment with cinacalcet in secondary hyperparathyroidism for dialysis patients: The will is good--but what about the evidence?]. Lakartidningen, 2013. 110(34-35): p. 1481-3

    Asker-Hagelberg C, Rydberg D, Hentschke M, Holm L, Rosenborg S, Elinder C-G, et al. Otydligt om läkemedelsdosering vid nedsatt njurfunktion [Unclear on dose adjustment in renal impairment]. Lakartidningen. 2013 May 22-28;110(21):1030-2

    Forslund T, Wettermark B, Wändell P, von Euler M, Hasselström J, Hjemdahl P. Risk Scoring and Thromboprophylactic Treatment of Patients with Atrial Fibrillation without and with Access to Primary Healthcare Data: Experience from the Stockholm Health Care System. Int J Cardiol 2013;170:208-14. PubMed

    Helldén A, Odar-Cederlöf I, Nilsson G, Sjöviker S, Söderström A, Euler Mv, Ohlén G, Bergman U. Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open 2013 Apr 11;3(4). PubMed

    Wass S, Carlsson B, Vimarlund V, Korkmaz S, Shemeikka T, Vég A. Towards Capturing Innovation Effects of a CDSS (NjuRen). Stud Health Technol Inform. 2013;192:1049. PubMed

    Malmström RE, Godman BB, Diogene E, Baumgärtel C, Bennie M, Bishop I, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013 May 14;4:39. PubMed

    Godman B, Finlayson AE, Cheema PK, Zebedin-Brandl E, Gutiérrez-Ibarluzea I, Jones J, et al. Personalizing health care: feasibility and future implications. BMC Med. 2013 Aug 13;11:179. PubMed

    Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Bengtsson Boström K, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol 2013;69:1955-64. PubMed

    Heibert Arnlind M, Wettermark B, Sjöborg B, Dahlén E, Loikas D, Wikström Jonsson E. Socioeconomic status and the quality of prescribing asthma drugs in Sweden. J Asthma 2013;50:842-9. PubMed

    Godman B, Persson ME, Miranda-Tellez J, Skiöld P, Wettermark B, Barbui C, et al. Changes in the utilisation of venlafaxine after the introduction of generics in Sweden. Appl Health Econ Health Policy 2013 Aug;11(4):383-93. PubMed

    Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Ljunggren G, Kahan T. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013 Sep;15(9):995-1002. PubMed

    Loikas D, Wettermark B, von Euler M, Bergman U, Schenck-Gustafsson K. Differences in drug utilisation between men and women - a cross sectional analysis of all dispensed drugs in Sweden. BMJ Open 2013 May 3;3(5). PubMed

    Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol 2013 May;69 Suppl 1:73-8. PubMed

    Schmidt-Mende K, Hasselström J. Systematisk klinisk bedömning av vikt vid läkemedelsgenomgångar [Drug utilization review--a practical example from primary care]. Läkartidningen 2013;110:1105-7

    Sen M, Rasjö Wrååk G, Rönmark P, Carlsson AC, Törnkvist L, Wändell P, et al. Lack of long-term effects from a pedagogical intervention upon blood pressure control--a randomized primary care study. Scand Cardiovasc J 2013 Oct;47(5):289-96. PubMed

    Godman B, Persson M, Miranda J, Barbui C, Bennie M, Finlayson A, et al. Can authorities take advantage of the availability of generic atypical antipsychotic drugs? Findings from Sweden and potential implications. Journal of Pharmaceutical Health Services Research 2013;4:139–150

    Cars T, Wettermark B, Malmström R, Ekeving G, Vikström B, Bergman U, et al. Extraction of electronic health record data in a hospital setting: comparison of automatic and semi-automatic methods using anti-TNF therapy as model. Basic Clin Pharmacol Toxicol 2013 Jun;112(6):392-400. PubMed

    Godman B, Wettermark B, Miranda J, Bennie M, Martin A, Malmström RE. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Int J Clin Pract 2013 Sep;67(9):853-62. PubMed

    Piccinni C, Raschi E, Poluzzi E, Puccini A, Cars T, Wettermark B, et al. Trends in antiarrhythmic drug use after marketing authorisation of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. Eur J Clin Pharmacol 2013 Mar;69(3):715-20. PubMed

    Andersson ML, Böttiger Y, Lindh JD, Wettermark B , Eiermann B. Impact of the of the drug-drug interaction database SFINX on prevalence of potentially serious drug-drug interactions in primary health care. Eur J Clin Pharmacol 2013 Mar;69(3):565-71. PubMed


    Bergqvist M, Karlsson EA, Björkstén KS, Ulfvarson J Medication Errors by Nurses in Sweden-Classification and Contributing factors. 2012. Open Access Scientific Reports. 1:527. doi:10.4172/scientificreports.527

    Godman B, Paterson K, Malmström RE, Selke G, Fagot JP, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res 2012 Aug;12(4):439-41. PubMed

    Ingemansson M, Wettermark B, Jonsson EW, Bredgard M, Jonsson M, Hedlin G, et al. Adherence to guidelines for drug treatment of asthma in children: potential for improvement in Swedish primary care. Qual Prim Care  2012;20(2):131-9. PubMed

    Godman B, Wettermark B, Bishop I, Burkhardt T, Fürst J, Garuoliene K, et al. European payer initiatives to reduce prescribing costs through use of generics. Gabi Journal 2012;1:22-7

    Rahmner PB, Eiermann B, Korkmaz S, Gustafsson LL, Gruvén M, Maxwell S, Eichle HG, Vég A. Physicians' reported needs of drug information at point of care in Sweden. Br J Clin Pharmacol 2012 Jan;73(1):115-25. PubMed


    Hjemdahl P, Allhammar A, Eklund J, Forslund T, Hulting J, Kahan T, et al. Visioner är bra men riktlinjer kräver evidens. [Visions are good but the guidelines require evidence]. Läkartidningen 2011;108:2444-5

    Hjemdahl P, Allhammar A, Eklund J, Forslund T, Hulting J, Kahan T, et al. Säg nej till extremerna i lipidsänkardebatten. Läkartidningen 2011;108:1664-5

    Rahmner PB, Lundborg M. Ansvaret för samlad läkemedelslista ska vara tydligt. Sveriges läkemedelskommittéer (LOK) har gett ut riktlinjer. Läkartidningen 2011;108:1250-2

    Rahmner PB, Eiermann B, Korkmaz S, Gustafsson LL, Gruvén M, Maxwell S, et al.. Physicians' reported needs of drug information at point of care in Sweden. Br J Clin Pharmacol. 2012 Jan;73(1):115-25. PubMed

    Loikas D, Wettermark B, von Euler M, Bergman U, Ringbäck Weitoft G, Schenck-Gustafsson K. Genus och läkemedel – en systematisk analys av könsskillnader i läkemedelsanvändningen i Sverige. Läkartidningen 2011; 108:1957-62

    Forslund T, Raaschou P, Hjemdahl P, Krakau I, Wettermark B. Usage Risk and Benefit of Weight-Loss Drugs in Primary Care. J Obes. 2011;2011:459263. PubMed

    Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Frontiers in Pharmacology 2011 Jan 7;1:141. PubMed

    Gustafsson  LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, et al for the Regional Drug Expert Consortium. The “Wise List”- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic & Clinical Pharmacology & Toxicology 2011;108:224-33. PubMed

    Nilsson A, Dahllöf J, Allerstrand G, Englund C, Pettersson G, Wettermark B. Individbaserade data om uthämtade recept - kvalitetsmått för primärvården. Läkartidningen 2011;108:471-4

    Qvarnström M, Wettermark B, Ljungman C, Zarrinkoub R, Hasselström J, Manhem K, et al. Antihypertensive treatment and control in a large primary care population of 21167 patients. J Hum Hypertens 2011;25:484-91 Pubmed

    Neovius M, Sundström A, Simard J, Wettermark B, Cars T, Feltelius N, Askling J, Klareskog L; for the ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol. 2011;40:8-15. Pubmed


    Persson M, Wilking N, Wettermark B. Rationell introduktion av nya cancerläkemedel. Horizon scanning med strukturerad uppföljning. Onkologi i Sverige 2010;2:54-60

    Wettermark B, Godman B, Eriksson C, van Ganse E, Garattini S, Joppi R, Malmström RE, Paterson K, Gustafsson LL. Einführung neuer Arzneimittel in europäische Gesundheitssysteme. [Introduction of new medicines into European healthcare systems.] GGW 2010;10:24–34

    Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):707-22 PubMed

    Godman B, Shrank W, Wettermark B, Andersen M, Burkhardt T, Garuloiene K, et al. Use of generics – a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 2010;3:2470-94 PubMed

    Wilking N, Jönsson B, Wettermark B. Användning av cancerläkemedel i Sverige och Europa. Läkartidningen 2010;107:1075-80

    Forslund T, Wettermark B, Raaschou P, Hjemdahl P, Krakau I. Bantningsläkemedel tycks inte göra någon nytta. Vårdcentraler skriver ut preparaten på lösa boliner, visar journalstudie. Läkartidningen 2010;107:910-3

    Arnlind MH, Wettermark B, Nokela M, Hjemdahl P, Rehnberg C, Jonsson EW.Regional variation and adherence to guidelines for drug treatment of asthma. Eur J Clin Pharmacol 2010;66:187-98. Pubmed

    Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC BMC Health Serv Res. 2010 Jun 7;10(1):153. [Epub ahead of print] Pubmed

    Mannheimer B, Wettermark B, Lundberg M, Pettersson H, von Bahr C, Eliasson E. Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions. Br J Clin Pharmacol 2010;69:411-7. Pubmed

    Wettermark B, Persson M, Wilking N, Kalin M, Korkmaz S, Hjemdahl P, et al for the Regional Drug Expert Consortium. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Services Research 2010;10:128. Pubmed

    Lexne E, Johansson E, Petersson G, Gustafsson LL. Effektiv och säker läkemedelsbehandling förutsätter användarvänligt IT-stöd med aktuell evidens. Läkartidningen 2010;107:102-5.

    Eiermann B,Bastholm-Rahmner P, Korkmaz S, Lilja B, Veg A, Wettermark B, et al. Knowledge databases for clinical decision support in drug prescribing-development, quality assurance, management, integration, implementation and evaluation of clinical value. Chapter in Clinical Decision Support, Vienna 2010.

    Kristianson K, Ljunggren H, Gustafsson LL. Data extraction from a semi structured electronic medical record system for outpatients: a model to facilitate the access and use of data for quality control and research. Health Informatics Journal 2010;15:305-19. Pubmed

    Rahmner P, Gustafsson LL, Holmstrom I, Rosenqvist U, Tomson G. "Who´s job is it anyway? Swedish general practioner´s perception of their responsibility for the patient´s drug list. Annals of Family Medicine 2010;8:40-6. Pubmed

    Wettermark B, Godman B, Neovius M, Hedberg N, Mellgren TO, Kahan T. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 2010;94:221-9. Pubmed


    Bergqvist M, Ulfvarson J, Karlsson EA. Nurseled medication reviews and the quality of drug treatment of elderly hospitalized patients. Eur J clin Pharmacol 2009;65:1089-96. PubMed

    Wettermark B. Nya möjligheter att studera om läkemedlen används rationellt. Chapter in Ringbäck Weitoft G. 4 år med Läkemedelsregistret. Socialstyrelsen, Stockholm 2009. ISBN: 978-91-86301-49-1. [Chapter in the publication celebrating the fourth anniversary of the Swedish Precsibed Drug register. National Board of Health and Welfare.]

    Persson M, Wilking N, Wettermark B. Utan spaning ingen aning. Om SLLs modell att förutspå introduktion av nya läkemedel. Pharma Industry 2009;6:28-32

    Helldén A, Bergman U, von Euler M, Hentschke M, Odar-Cederlöf I, Ohlén G. Adverse drug reactions and impaired renal function in elderly patients admitted to the emergency department: a retrospective study. Drugs Ageing 2009; 26:595-606. Pubmed

    Bastholm Rahmner P, Gustafsson LL, Larsson J, Rosenqvist U, Tomson G, Holmström I. Variations in understanding the drug-prescribing process: a qualitative study among Swedish GPS. Family Practice 2009;26:121-7. Pubmed

    Allhammar A, Heaton C, Hulting J, Kahan T, Malmström R, Martinsson A, et al. Läksaks expertgrupp för hjärt-kärlsjukdomar. Vi rekommenderar simvastatin (20-) 40 mg dagligen. Läkartidningen 2009;106:2550-1.

    Holmström M, Johnsson H, Lärfars G, Malmström R, Hjemdahl P. Nytt medel vid förmaksflimmer - hur fungerar det i vanlig sjukvård? Läkartidningen 2009;106: 3019-21

    Gustafsson LL, Wettermark B, Kalin M, Korkmaz S, Persson ME, Almkvist H, et al. Rationell introduktion av nya läkemedel kräver både ett sjukvårds- och samhällsperspektiv. Läkartidningen 2009;106:52

    Hjemdahl P, Allhammar A, Heaton C, Hulting J, Kahan T, Malmström R, et al. SBU bör utreda vad som är en evidensbaserad och kostnadseffektiv statinanvändning. [SBU should investigate what is an evidence-based and cost-effective use of statins] Läkartidningen 2009;32:1992-4

    Wettermark B, Jacobsson B, Godman B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl Health Econ Health Policy. 2009;7(3):137-47 PubMed

    Wettermark B, Ångman A, Hjemdahl P. Fullt möjligt minska kostnaderna för behandling av hypertoni. [Fully possible to reduce the costs of hypertension treatment] Läkartidningen 2009;106:1558-62

    Norman C, Zarrinkoub R, Hasselström J, Godman B, Granath F, Wettermark B. Potential savings without compromising the quality of care. Int J Clin Pract 2009;63:1320-6. Pubmed

    Wettermark B, Pehrsson A, Juhasz-Haverinen M, Veg A, Edlert M, Törnwall-Bergendahl G, et al. Financial incentives linked to self-assessment of prescribing patterns – a new approach for quality improvement of drug prescribing in primary care. Quality in Primary Care 2009;17:179–89. Pubmed

    Böttiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML, et al. SFINX-a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol. 2009;65:627-33. Pubmed

    Godman B, Wettermark B, Hoffman M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev Pharmacoeconomcis Outcomes Research 2009; 9:65-83. Pubmed

    Castensson S, Eriksson V, Lindborg K, Wettermark B. A method to include the environmental hazard in drug prescribing. Pharm World Sci 2009;31:24-31. Pubmed


    Mannheimer B, Ulfvarson J, Eklöf S, Bergqvist M, von Bahr C. A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol. 2008 Dec;64(12):1209-14. PubMed

    Odar-Cederlöf I, Oskarsson P, Ohlén G, Tesfa Y, Bergendal A, Helldén A, Bergman U. Läkemedelsbiverkan som orsak till inläggning på sjukhus. Vanliga medel står för merparten, visar tvärsnittsstudie [Adverse drug effect as cause of hospital admission. Common drugs are the major part according to the cross-sectional study]. Läkartidningen 2008;105:890-3

    André M, Andersén-Karlsson E, Landahl S, Löfmark R, Silfverhielm B, Skoglund I. Statens beslut, landstingens kassa och min patient. [Decisions by the state, county council's money and my patient. Consequences of the LFN survey of antihypertensive agents]. Läkartidningen 2008;105:1549-50

    Andersén-Karlsson E, Palmér M. Malmström R. Nya läkemedel mot typ 2-diabetes otillräckligt dokumenterade över tid. Läkartidningen 2008;105:647-8

    Shemeikka T, Gustafsson LL, Korkmaz S. Krav på säkra datasystem för läkemedelsstöd. Läkartidningen 2008;105:3177-8

    Frisk P, Mellgren TO, Hedberg N, Berlin A, Granath F, Wettermark B. Utilisation of angiotensin receptor blockers in Sweden: combining survey and register data to study adherence to prescribing guidelines. Eur J Clin Pharmacol 2008;64:1223-9. Pubmed

    Esbjörn P, End-Rodrigues T, Thylén P, Bergman U. Läkemedelsbiverkan vanlig orsak till sjukhusvård av äldre. En klinisk retrospektiv studie. Läkartidningen 2008;105: 2338-42.

    Bergqvist M, Ulfvarson J, Andersen Karlsson E, von Bahr C. A nurse-led intervention for identification of drug-related problems. Eur J Clin Pharmacol. 2008 May;64(5):451-6. PubMed

    Almkvist H, Bergman U, Edlert M, Juhasz-Haverinen M, Pehrsson Å, Thörnwall-Bergendahl G, et al. Stockholms läns landstings modell för decentraliserat kostnadsansvar. Kvalitetsbokslut minskade läkemedels-kostnaderna i primärvården. Läkartidningen 2008;105:2930-4

    Gustafsson L.L. Almkvist H, Hjemdahl P, Julander M, Kalin M, Korkmaz S, et al. Modell för strukturerad introduktion av nya läkemedel – syftet är att erbjuda alla patienter ändamålsenligt behandling. Läkartidningen 2008;105:2917-22

    Wettermark B, Raaschou P, Forslund P, Hjemdahl P. Acomplia är indicerat för viktminskning, inte för riskreduktion. Läkartidningen 2008;105:145-6

    Jägestedt M, Ronge S, Wettermark B, Andersen-Karlsson E. Kritiska framgångsfaktorer för rationell läkemedelsanvändning på vårdcentral. [Rational drug prescription: a question of knowledge and direction. Qualitative study at ten community health centers in the county of Stockholm] Läkartidningen 2008;105:2924-29

    Wettermark B, Persson A, von Euler M. Secondary prevention in a large stroke population – a study of patients’ purchase of recommended drugs. Stroke. 2008 Oct;39(10):2880-5. PubMed

    Wettermark  B, Godman B, Andersson K, Gustafsson LL, Haycox A,  Bertele V.  Recent national and regional drug reforms in Sweden – implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26(7):537-50. PubMed

    Garattini S, Bertele V, Godman B, Haycox A, Wettermark B, Gustafsson LL. Enhancing the rational use of new medicines across European healthcare systems – A Position Paper. Eur Jn Clinical Pharmacology 2008; 64:1137–8. Pubmed


    Ulfvarson J, Mejyr S, Bergman U. Nurses are increasingly involved in pharmacovigilance in Sweden. Pharmacoepidemiol Drug Saf. 2007 May;16(5):532-7. PubMed

    Wettermark B, Raaschou P, Forslund T, Hjemdahl P. Fortsatta frågetecken kring bantningsmedlet rimonabant. Inte godkänt i USA på grund av risken för psykiska biverkningar. Läkartidningen 2007:105: 3879-81

    Sjöborg B, Bäckström T, Arvidsson LB, Andersén-Karlsson E, Blomberg LB, Eiermann B, et al. Design and implementation of a point-of-care computerized system for drug therapy in Stockholm metropolitan health region - Bridging the gap between knowledge and practice. Int J Med Inform 2007;76:497-506. Pubmed

    Hoffmann M, Gustafsson LL, Korkmaz S, Böttiger Y, Sjöqvist F. Läkare, läkemedel och IT - mer engagemeng krävs. Läkartidningen 2007;104;393-4


    Mannheimer B, Ulfvarson J, Eklöf S, Bergqvist M, Andersén-Karlsson E, Pettersson H, von Bahr C. Drug-related problems and pharmacotherapeutic advisory intervention at a medicine clinic. Eur J Clin Pharmacol. 2006 Dec;62(12):1075-81. PubMed

    Wettermark B, Korkmaz S, Gustafsson LL, Iwarson S. Läkemedelskommittéernas genomslag ökar. [Increased adherence to recommendations from the Swedish Drug and Therapeutics Committees] Pharma Industry 2006;9(2):52-7

    Wettermark B, Tomson G, Bergman U. Kvalitetsindikatorer för läkemedel – läget i Sverige idag. [Quality indicators for drug prescribing--the situation in Sweden] Läkartidningen 2006;103:3607-11

    Wettermark B, Tomson G, Bergman U. Kvalitetsindikatorer för läkemedel – nya europeiska rekommendationer för terminologi, validering och användning. [Quality indicators for drug utilization--new European recommendations] Läkartidningen 2006;103:3469-72

    Wettermark B, Vlahovic-Palcevski V, Laing R, Bergman U. Adherence to WHOs Essential Medicines List in two European countries. WHO Drug Information 2006;20:78-85

    Wettermark B, Bergman U, Krakau I. Using aggregate data on dispensed drugs to evaluate the quality of prescribing in urban primary healthcare in Sweden. Public Health. 2006 May;120(5):451-61. PubMed

    von Euler M, Eliasson E, Ohlén G, Bergman U. Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization. Pharmacoepidemiol Drug Saf 2006;15:179-84. Pubmed


    Gustafsson LL. Läkemedelskommittéerna främjar klok läkemedels-användning. Läkartidningen 2005;102;882

    Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf 2005; 14:579-88. Pubmed


    Hellström PM, Vitols S. The choice of proton pump inhibitor: does it matter? Basic Clin Pharmacol Toxicol. 2004 Mar;94(3):106-11. PubMed

    Andersén Karlsson E, Hedman P. Läkemedelsreklam till allmänheten ger negativa effekter i patient–läkarförhållandet. [Consumer drug advertising has negative effects on the patient-physician relationship]. Läkartidningen 2004;101:2078-9

    Wettermark B, Nyman K, Bergman U. Five years’ experience of quality assurance and feedback with individual prescribing profiles at a primary healthcare centre in Stockholm, Sweden. Quality in Primary Care 2004;12(3):225-34

    Bastholm-Rahmner P, Andersén-Karlsson E, Arnhjort T, Eliasson M, Gustafsson LL, Jacobsson L, et al. Physicians' perceptions of possibilities and obstacles prior to implementing a computerised drug prescribing support system. Int J Health Care Quality Assurance 2004;17:173-9.

    Bergman U, Risinggård H, Vlahović-Palcevski V, Ericsson O. Use of antibiotics at hospitals in Stockholm: a benchmarking project using internet. Pharmacoepidemiol Drug Saf 2004;13:465-71. Pubmed

    Gustafsson LL. Val av hypertonibehandling - ringa roll för doxazosin (Alfadil). Hur implementerar vi evidensbaserade rekommendationer? Läkartidningen 2004;101:228-9


    Wettermark B, Pehrsson A, Jinnerot D, Bergman U. Drug utilisation 90% profiles - a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf 2003;12:499-510. Pubmed

    Hellström PM, Vitols S. Samtliga protonpumpshämmare har likvärdig effekt i standarddoser. [All proton pump inhibitors are equally efficacious in standard dosages]. Läkartidningen 2003;100:2212-6

    Gustafsson LL, Widäng K, Hoffmann M, Andersén-Karlsson E, Elfman K, Johansson B, et al. Beslutsstöd vid läkemedelsförskrivning II: Vilken information skall de innehålla? Läkartidningen 2003;15: 1338-44

    Gustafsson LL, Widäng K, Hoffmann M, Andersén-Karlsson E, Elfman K, Johansson B, et al. Beslutsstöd vid läkemedelsförskrivning I: Bättre säkerhet för patienten och effektivare behandling. Läkartidningen 2003; 15;1333-7.


    Vlahovic-Palcevski V, Wettermark B, Bergman U. Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). Eur J Eur J Clin Pharmacol. 2002 Jun;58(3):209-14. PubMed

    Sjöqvist F, Bergman U, Dahl ML, Gustafsson LL, Hensjö LO. Drug and therapeutics committees: a Swedish experience. WHO Drug Information 2002; 16:207-13


    Sarlöv C, Andersén-Karlsson E, von Bahr C. Läkemedelsbiverkningar leder till sjukhusvård för hjärtpatienter.[Adverse effects of drugs in patients with heart disease lead to hospital care]. Lakartidningen. 2001;98(47):5349-53 Swedish. PubMed

    Wettermark B, Hjemdahl P. Har vi råd med en bra kolesterolsänkande behandling? Budgetunderlag för behovsbaserade statinkostnader i Stockholms län. Läkartidningen 2001;99:5472-83

    Nyman K, Bergens A, Björin AS, Guterstam P, Nyrén O, Jansson U, et al. U. Återföring av förskrivningsprofiler vid en vårdcentral. Viktigt inslag i kvalitetssäkringen av läkemedelförskrivningen. Läkartidningen 2001;98:160-4

    Engfeldt P, Popa C, Bergensand P, Bernsten C, Lindgren O, Navay I, et al. Kvalitetsarbete kring läkemedelsförskrivning i primärvården. Nytt databasprogram underlättar uppföljning av läkemedelsbehandling. Läkartidningen 2001:98:5767-71

    Nilsson G, Hjemdahl P, Hässler A, Vitols S, Wallén NH, Krakau I. Feedback on prescribing rate combined with problem-oriented pharmacotherapy education as a model to improve prescribing behaviour among general practitioners. Eur J Clin Pharmacol. 2001 Jan-Feb;56(11):843-8. PubMed

    Gustafsson LL, Eliasson M, Bastholm P, Hadad K, Henriksson K, Jacobsson L, et al. Janus – a computerized system for rational drug treatment and drug research. NLN News 2001;14:4-6.

    Sjöqvist F. Skärpta krav på ojävig hantering vid val av läkemedel. Ledamöter i Stockholms läkemedelskommittéer lämnar årlig jävsdeklaration. Läkartidningen 2001:99:541-3


    Isacsson G, Wettermark B, Bergman U. Ökad psykofarmakaanvändning hos unga - soten är problemet, inte boten! (debattartikel). [Increased use of psychopharmaceuticals among young people--a problem not a cure!] Läkartidningen 2000;16:1986-7

    Gustafsson LL, Hensjö LO. Läksak stödjer klok läkemedelsbehandling genom att använda kunskap och vassa IT-verktyg. Läkartidningen 2000; 97:4347



    Bergman U, Popa C, Tomson Y, Wettermark B, Einarson TR, Åberg H, et al. Drug utilization 90%--a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol 1998; 54:113-8. Pubmed

    Bergman U, Wettermark B, Myrhed M, Arrhenius L. DU90% nytt kvalitetsmått på läkemedelsförskrivningen. Icke-steroida antiinflammatoriska medel exempel för analys. Läkartidningen 1998;95:4237-42


    Tomson Y, Hasselström J, Tomson G, Aberg H. Asthma education for Swedish primary care physicians--a study on the effects of "academic detailing" on practice and patient knowledge. Eur J Clin Pharmacol. 1997;53(3-4):191-6. PubMed


    Bergman U, Myrhed U. Åtta läkemedelskommittéers listor jämförda. Antalet preparat varierar mycket. Likartad syn på dyraste medlen. Lakartidningen. 1996 Apr 10;93(15):1459-60

    Uppdaterad: 2017-07-03

    Hitta i sidan

      För frågor och tips till oss: